about
Dipeptidyl-peptidase (DPP)-4 inhibitors or glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitusDiscovery of gastric inhibitory polypeptide and its subsequent fate: Personal reflectionsIn Vivo Models for Incretin Research: From the Intestine to the Whole BodyThe class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitusGLP-1-based strategies: a physiological analysis of differential mode of actionGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesStructure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptorsEffect of duodenectomy on gastric motility and gastric hormones in dogsGlucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout miceGlucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in ratcDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effectsThe expression and function of glucose-dependent insulinotropic polypeptide in the embryonic mouse pancreasGlucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and manExtrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure.Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model.An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics.An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers.Current status of islet cell replacement and regeneration therapy.Effect of gastric bypass surgery on the incretinsIs the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls.The evolving place of incretin-based therapies in type 2 diabetesUpper gastrointestinal function and glycemic control in diabetes mellitus.Differential acute postprandial effects of processed meat and isocaloric vegan meals on the gastrointestinal hormone response in subjects suffering from type 2 diabetes and healthy controls: a randomized crossover study.Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.Importance of preabsorptive insulin release on oral glucose tolerance: studies in pancreatic islet transplanted rats.Incretin-based therapies in prediabetes: Current evidence and future perspectivesInterleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.Determining predictors of early response to exenatide in patients with type 2 diabetes mellitusExenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetesβ-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity.Physiology of incretins in health and disease.Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitusEffects of High Glucose Levels and Glycated Serum on GIP Responsiveness in the Pancreatic Beta Cell Line HIT-T15.Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetesDipeptidyl peptidase-4 expression in pancreatic tissue from patients with congenital hyperinsulinismThe incretins: a link between nutrients and well-being.The GLP-1 system as a therapeutic target.Laparoscopic Roux-en-Y gastric bypass with ileal transposition - an alternative surgical treatment for type 2 diabetes mellitus and gastroesophageal reflux.Glucagon-like peptide-1(7-36) amide is a new incretin/enterogastrone candidate.
P2860
Q24185805-9E6A762F-E8C1-4A93-8820-1383ECA4C794Q26749226-379AD78F-7709-465D-9B44-BB5C2AB65215Q26753185-ADEC7328-AF23-43BF-8CD5-1AEB8C411E0DQ26828940-25C13231-5148-412A-AA3F-CAB291BD755BQ26997149-7F82263E-F108-4EC7-B436-2925C1627AF3Q28067465-F421DF3F-0ED5-4235-AD3F-F07908A7EF50Q28203273-EFFD5D9D-0B04-4F27-AE06-3CD6193A59B2Q28354071-15D9C13B-C2C9-4E03-8A01-5584D8697362Q28510783-98267643-BB38-4B1C-AAC0-FD98DA63EA3EQ28573441-9A85CE73-77DF-43A1-99F0-B483585B0491Q28574297-C6E16593-BC4C-40FC-ACB4-D32D3547C54AQ28590140-0D9DDB20-1104-486F-BDB1-B3BED4E3DECFQ28609252-E645D11B-C3D7-408D-99F5-D18A4CDADE47Q30478488-8149C0B4-9FEA-4C9E-9882-098A2B5326FEQ30578482-20F197E6-126F-4EEE-BC02-5E401A193140Q31131623-AD2CFA1B-4A98-4E11-9722-F59BA42E3FCFQ33516679-C653C94F-B06D-417F-A587-AD879B449B8CQ33738705-CC42F947-9058-4C1C-B559-A12981D96619Q33743998-5618EB0A-64F7-4F79-85EE-FAB04A761310Q33803409-169EB86B-E3C0-4828-93D8-4D2A8EC5884DQ33866576-E26ECFDD-C6B0-4655-9B4B-3089A7F60B17Q33866808-A5408163-B0B6-48C2-B7DA-A198B0817CF9Q33869207-B753771A-04C9-45A5-B808-592D80033260Q34184127-5B82CF67-B0AD-4942-B04D-E5520FF63F87Q34278297-C498C5DE-A1B2-4896-8B4F-4FC12E478329Q34493811-058E7AD6-7B82-4B10-AF42-032136EB22ADQ34699191-560DBD21-48D1-4350-8D05-F68770820C15Q34857481-2B6D0EEC-FBD7-4459-A51C-16AD4C8424A1Q35061423-FF44A236-2A18-4CAE-AAE7-5437A3DFE6F9Q35183579-65BEE7DF-8709-4DE0-9324-122198762640Q35680897-A1201C53-8D41-480C-9B74-C9EBF9097CCBQ35760279-1205B4BE-6C00-4BD6-898B-BC0749D0DDA9Q35824086-9877ADB7-1595-494D-8074-52763F17D7AEQ35843905-64A9C328-4563-47E2-A6F2-06FA912270C5Q36012896-057B4C09-6CD1-425C-90FB-527C2877130DQ36014334-7801DEEE-D9D7-47F2-AC17-2ED26612F9ECQ36118673-CC96098C-4CC2-4B86-87FE-0B53A8C7A2B6Q36265221-69983464-2F21-4E58-B884-F6137B0B573CQ36300596-38F89611-1003-456A-B4F1-84628B0FCD8FQ36396952-F7E29135-FCE0-45AA-A830-CBBE762A7027
P2860
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
1979年论文
@zh
1979年论文
@zh-cn
name
The incretin concept today.
@en
The incretin concept today.
@nl
type
label
The incretin concept today.
@en
The incretin concept today.
@nl
prefLabel
The incretin concept today.
@en
The incretin concept today.
@nl
P356
P1433
P1476
The incretin concept today.
@en
P2093
W Creutzfeldt
P2888
P356
10.1007/BF01225454
P577
1979-02-01T00:00:00Z